AFQ065 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
6Parkinson disease2

6. Parkinson disease


Clinical trials : 2,307 Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-019418-25-DE
(EUCTR)
01/10/201019/07/2010Open label, safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesiasAn open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 16.0;Level: HLT;Classification code 10013929;Term: Dyskinesias and movement disorders NEC;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AFQ056
Product Code: AFQ065
Product Name: AFQ056
Product Code: AFQ065
Novartis Pharma Sevices AGNULLNot RecruitingFemale: yes
Male: yes
244France;Canada;Finland;Australia;Germany;Italy;Japan
2EUCTR2010-019418-25-FI
(EUCTR)
08/09/201021/07/2010An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesiasAn open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson’s patients with L-dopa induced dyskinesias Moderate to severe levodopa induced dyskinesia in patients with Parkinson's disease
MedDRA version: 12.1;Level: LLT;Classification code 10013916;Term: Dyskinesia
Product Name: AFQ056
Product Code: AFQ065
Product Name: AFQ056
Product Code: AFQ065
Product Name: AFQ056
Product Code: AFQ065
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
244France;Finland;Germany;Italy